Personalised Medicine with IL-23 Blockers: Myth or Reality?

ABSTRACT:

Background and aims

The medical management of inflammatory bowel disease [IBD] has become increasingly targeted, through the identification of specific immune mediators involved in its pathogenesis. IL-23 is an inflammatory cytokine involved in both innate and adaptive immunity, which has been identified as a therapeutic target in Crohn's disease [CD] and ulcerative colitis [UC] through its upstream inhibition of the T helper 17 [Th17] pathway. We sought to review available data on the efficacy of IL-23 inhibitors in the treatment of IBD and the potential for clinical and molecular predictors of response to facilitate a personalised medicine approach with these agents.

Methods

We reviewed and summarised available clinical trial data on the use of the IL-23 inhibitors risanki

SUBMITTER: Gottlieb ZS 

PROVIDER: S-EPMC9113162 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature